# Satellos Bioscience Inc.: overview MSLE · Nasdaq · CIK 1421642 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/msle.md) · [Financials](/companies/msle/financials.md) · [Filings](/companies/msle/filings.md) · [Insiders](/companies/msle/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $m | not reported | not reported | | Gross margin | % | not reported | not reported | | Operating margin | % | not reported | not reported | | Net margin | % | not reported | not reported | | Diluted EPS | $ per share | [(2.16)](/filings/0001104659-26-035729.md) | [(1.70)](/filings/0001104659-26-035729.md) | | Free cash flow | $m | [(18.3)](/filings/0001104659-26-035729.md) | [(23.6)](/filings/0001104659-26-035729.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/msle/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $7.2m | 938,666 | | Unchanged | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $6.9m | 892,074 | | Unchanged | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $6.3m | 813,666 | | Unchanged | | [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $5.3m | 682,700 | | Reduced −8,078 | | [SPHERA FUNDS MANAGEMENT LTD.](/funds/1496201.md) | 2026-06-30 | $5.1m | 652,590 | | Added +163,383 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $3.9m | 500,432 | | Unchanged | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $3.7m | 491,624 | | Added +391,624 | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $3.7m | 475,000 | | Unchanged | | [Avidity Partners Management LP](/funds/1791827.md) | 2026-06-30 | $3.0m | 387,769 | | Unchanged | | [Saturn V Capital Management LP](/funds/1964437.md) | 2026-06-30 | $2.7m | 350,000 | | Unchanged | ## Recent filings [All 52 filings](/companies/msle/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 07:00 ET | [6-K](/filings/0001171843-26-006835.md) | Report of a foreign private issuer, period 2026-10-27 | 0001171843-26-006835 | | 2026-10-21 | 07:00 ET | [6-K](/filings/0001171843-26-006724.md) | Report of a foreign private issuer, period 2026-10-21 | 0001171843-26-006724 | | 2026-10-05 | 07:00 ET | [6-K](/filings/0001171843-26-006380.md) | Report of a foreign private issuer, period 2026-10-05 | 0001171843-26-006380 | | 2026-09-30 | 07:00 ET | [6-K](/filings/0001171843-26-006303.md) | Report of a foreign private issuer, period 2026-09-30 | 0001171843-26-006303 | | 2026-09-24 | 07:00 ET | [6-K](/filings/0001171843-26-006202.md) | Report of a foreign private issuer, period 2026-09-24 | 0001171843-26-006202 | | 2026-09-15 | 07:00 ET | [6-K](/filings/0001171843-26-006046.md) | Report of a foreign private issuer, period 2026-09-15 | 0001171843-26-006046 | | 2026-09-09 | 07:00 ET | [6-K](/filings/0001171843-26-005936.md) | Report of a foreign private issuer, period 2026-09-09 | 0001171843-26-005936 | | 2026-09-01 | 07:00 ET | [6-K](/filings/0001171843-26-005825.md) | Report of a foreign private issuer, period 2026-09-01 | 0001171843-26-005825 | | 2026-08-14 | 16:31 ET | [6-K](/filings/0001104659-26-097247.md) | Report of a foreign private issuer, period 2026-08-14 | 0001104659-26-097247 | | 2026-08-13 | 17:03 ET | [6-K](/filings/0001171843-26-005503.md) | Report of a foreign private issuer, period 2026-06-30 | 0001171843-26-005503 | ## Latest annual report [Form 40-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-035729.md), filed Mar 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1421642 - Tickers: MSLE - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: Z4 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 07:01 ET. No prices; not investment advice.